Your browser doesn't support javascript.
loading
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease.
Krishnamurti, Lakshmanan; Liang, Jingchen; He, Zili; Deng, Yanhong; Nallagatla, Vineetha R; Hamidi, Rohaum; Flagg, Aron; Shah, Niketa.
Afiliação
  • Krishnamurti L; Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT.
  • Liang J; Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT.
  • He Z; Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT.
  • Deng Y; Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT.
  • Nallagatla VR; Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT.
  • Hamidi R; Yale New Haven Children's Hospital, New Haven, CT.
  • Flagg A; Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT.
  • Shah N; Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT.
Blood Adv ; 8(8): 1908-1919, 2024 Apr 23.
Article em En | MEDLINE | ID: mdl-38324722
ABSTRACT
ABSTRACT Vaso-occlusive episodes (VOC) or pain crises are the most common indications for hematopoietic cell transplantation (HCT) for sickle cell disease (SCD). Elimination of pain crisis after HCT is an important patient-centered outcome and may improve understanding of the natural history of pain syndromes in SCD. We examined deidentified records of 763 patients followed-up for a median of 36.7 months (range, 0.3-168.6 months), with 69.6% patient's age <18 years at HCT, 83.3% patient's Karnofsky-Lansky performance score (KPS) ≥90, overall survival 92.9%, event-free survival 72.4%, graft failure (GF) 22.4%, AGVHD 21.4%, CGVHD 27%, and pain crisis 8.65%. On unadjusted logistic regression, increased risk of pain crisis after HCT was observed in patient's aged >10 years at HCT (range, 11-17 years; OR, 9.43; 95% CI, 3.20-27.79; P < .0001), in age ≥18 years (OR, 16.62; 95% CI, 5.85-47.16; P < .0001), in those with history of pain crisis 2 years before HCT (OR, 13.16; 95% CI, 4.08-42.42; P < .0001), alternate donors (haploidentical [OR, 4.80; 95% CI, 2.48-9.31; P < .0001], unrelated matched [OR, 2.71; 95% CI, 1.23-5.97; P = .0132], and mismatched unrelated [OR, 3.19; 95% CI, 1.44-7.05; P = .0041], and those with GF (n = 41 [5.37%]; OR, 7.15; 95% CI, 4.20-12.18; P < .0001). Pain crisis was less frequent with KPS of ≥90 (OR, 0.31; 95% CI, 0.18-0.55; P < .0001). Multivariable logistic regression models confirmed age at HCT, KPS, graft type, donor type, history of VOC 2 years before HCT, and GF as independent predictors of pain crisis after HCT and generated predictive models and nomograms for pain crisis after HCT for SCD, which can support shared decision making.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Compostos Orgânicos Voláteis / Anemia Falciforme Tipo de estudo: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Compostos Orgânicos Voláteis / Anemia Falciforme Tipo de estudo: Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2024 Tipo de documento: Article